Q1 2017 TG Therapeutics Inc Earnings Call

5/5/2017 8:30

Conference Call TG Therapeutics Inc

TG Therapeutics Inc Conference call or earnings call will be held on May 5, 2017 During the earnings conference call's session TG Therapeutics Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conference call the bridge access number and key in the PIN code, Contact TG Therapeutics Inc for this information
Schedule a conference call with QCONF and get 5 free conference calls.
We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs seeking to develop IRAK4 (interleukin-1 receptor-associated kinase 4) inhibitors and anti-PD-L1 and anti-GITR antibodies.    
Read more Conference Call

TG Therapeutics Inc (TGTX)

3 Columbus Circle, New York New York 10019, United States